Skip to Main Content

Author Details

Rosina T Lis
National Cancer Institute
1992
61
32
PMIDPaper TitleJournal TitlePublished Year
36125519Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.Mol Cancer Res2023
35227084Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.J Urol2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
33023952Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.Clin Cancer Res2021
33683939Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.J Urol2021
33849963Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.Clin Cancer Res2021
33785256Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.Eur Urol2021
34496240Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.Cell Rep2021
33168599Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.Mol Cancer Res2021
31318977Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.Int J Cancer2020
32054861A case report of multiple primary prostate tumors with differential drug sensitivity.Nat Commun2020
31862185Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study.Acad Radiol2020
32690948Prostate cancer reactivates developmental epigenomic programs during metastatic progression.Nat Genet2020
30301696A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.Eur Urol2019
30811282Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.J Clin Oncol2019
29141848MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.Cancer Epidemiol Biomarkers Prev2018
30108097A Prospective Study of Aspirin Use and Prostate Cancer Risk by <i>TMPRSS2:ERG</i> Status.Cancer Epidemiol Biomarkers Prev2018
29921690Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.Cancer Res2018
29167279Height, Obesity, and the Risk of <i>TMPRSS2:ERG</i>-Defined Prostate Cancer.Cancer Epidemiol Biomarkers Prev2018
27683182A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2017
28151719Neoadjuvant Enzalutamide Prior to Prostatectomy.Clin Cancer Res2017
28871082Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.Nat Commun2017
28611215Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.Proc Natl Acad Sci U S A2017
28893901Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.Clin Cancer Res2017
28057717Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment.Mol Cancer Res2017
27663590Prognostic Utility of a New mRNA Expression Signature of Gleason Score.Clin Cancer Res2017
27899381Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.Cancer Res2017
26018610Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it!Histopathology2016
27115058Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression.J Clin Endocrinol Metab2016
26941365Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.Cancer Epidemiol Biomarkers Prev2016
26941287The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women.Cancer Res2016
26778300Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.Clin Genitourin Cancer2016
26817504Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.Am J Clin Nutr2016
25320358Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.Clin Cancer Res2015
29900095Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LCâ¿¿MSâ¿¿A technical report.EuPA Open Proteom2015
28843286Integrative Clinical Genomics of Advanced Prostate Cancer.Cell2015
26457646The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.Nat Genet2015
26469352Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.Prostate2015
25937617Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.J Mol Diagn2015
26000489Integrative clinical genomics of advanced prostate cancer.Cell2015
25728532The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.Prostate2015
24687926SPINK1 protein expression and prostate cancer progression.Clin Cancer Res2014
25311217Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.J Clin Oncol2014
24752078Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.Nat Biotechnol2014
24846059FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.Cancer Med2014
24925673Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer.Cancer Epidemiol Biomarkers Prev2014
23553268Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.Neuro Oncol2013
24292212Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.J Natl Cancer Inst2013
24130224Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.Cancer Epidemiol Biomarkers Prev2013
23983239Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.Cancer Epidemiol Biomarkers Prev2013
  • 1 - 50 of 61

Recommended Authors

Mandeep Takhar
GenomeDx Biosciences Inc.
Career Start Year 2010
Number of shared co-authors 22
Kyung Park
New York University Langone Health
Career Start Year 2010
Number of shared co-authors 31
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 11
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 38
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 16
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 26
Christina M??ller-Koop
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2006
Number of shared co-authors 1
Elai Davicioni
Veracyte Inc.
Career Start Year 2006
Number of shared co-authors 63
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 3
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 12
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 13
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 12
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 57
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 20
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 23
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 9
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 37
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 32
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 29
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 54
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 9
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 44
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 30
Claudia Hube-Magg
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1997
Number of shared co-authors 0
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 42
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 42
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 17
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 39
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 25
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 14

Collaborators

Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 43
Lorelei A Mucci
Co-authored papers 23
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 21
Edward L Giovannucci
Harvard T.H. Chan School of Public Health
Co-authored papers 16
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 15
Kathryn L Penney
Co-authored papers 13
Meir J Stampfer
Brigham and Women's Hospital
Co-authored papers 13
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 10
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 9
Huihui Ye
College of Optical Science and Engineering, Zhejiang University
Co-authored papers 9
Michaela Bowden
Dana-Farber Cancer Institute
Co-authored papers 9
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 8
Adam G Sowalsky
National Cancer Institute
Co-authored papers 7
Elahe A Mostaghel
University of Washington
Co-authored papers 6
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 6
Myles Brown
Co-authored papers 5
Mark M Pomerantz
Dana-Farber Cancer Institute
Co-authored papers 5
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Co-authored papers 5
Giovanni Parmigiani
Dana Farber Cancer Institute.
Co-authored papers 5
Lawrence D True
University of Washington School of Medicine
Co-authored papers 5
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 4
Stephanie A Harmon
National Cancer Institute, National Institutes of Health
Co-authored papers 4
Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Co-authored papers 4
Baris Turkbey
National Cancer Institute, National Institutes of Health
Co-authored papers 4
Stephen R Plymate
University of Washington
Co-authored papers 4
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 4
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 3
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 3
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 3
Stephen R Pennington
UCD Conway Institute, University College Dublin
Co-authored papers 3
Release 1.2